1-5 of 5
Cornelia Kolberg-Liedtke
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract P2-05-01: Telemedicine in physical therapy after axillary surgery for early breast cancer

Free
Hans-Christian Kolberg, Johanna Schmitz, Isabella Swienty, Leyla Akpolat-Basci, Özlem Yüksel, Abdrhman Maguz, Carsten Lehment, Miltiades Stephanou, Cornelia Kolberg-Liedtke
Journal: Clinical Cancer Research
Clin Cancer Res (2025) 31 (12_Supplement): P2-05-01.
https://doi.org/10.1158/1557-3265.SABCS24-P2-05-01
Published: 13 June 2025
View article titled, Abstract P2-05-01: Telemedicine in physical therapy after axillary surgery for early breast cancer
Journal Articles

Abstract PS17-07: Comparison of an Atezolizumab monotherapy window followed by Atezolizumab and chemotherapy vs. Atezolizumab and chemotherapy alone in high-risk triple-negative breast cancer (TNBC) – a subgroup analysis of the neoadjuvant neoMono trial

Free
Hans-Christian Kolberg, Johannes Schumacher, Ramona Erber, Michael Braun, Peter A. Fasching, Eva-Maria Grischke, Christian Schem, Michael P. Lux, Mustafa Deryal, Oliver Hoffmann, Bernhard Heinrich, Georg Kunz, Kristina Lübbe, Petra Krabisch, Arndt Hartmann, Philip Raeth, Sabine Kasimir-Bauer, Cornelia Kolberg-Liedtke
Journal: Clinical Cancer Research
Clin Cancer Res (2025) 31 (12_Supplement): PS17-07.
https://doi.org/10.1158/1557-3265.SABCS24-PS17-07
Published: 13 June 2025
View article titled, Abstract PS17-07: Comparison of an Atezolizumab monotherapy window followed by Atezolizumab and chemotherapy vs. Atezolizumab and chemotherapy alone in high-risk triple-negative breast cancer (TNBC) – a subgroup analysis of the neoadjuvant neoMono trial
Journal Articles

Abstract P2-11-17: Atezolizumab in combination w/ polychemotherapy w/ or without a pretherapeutic immune therapy window in patients w/ early triple negative breast cancer (eTNBC) & low tumor burden – prospective data from the randomized neoadjuvant neoMono trial

Free
Cornelia Kolberg-Liedtke, Johannes Schumacher, Ramona Erber, Michael Braun, Peter A. Fasching, Eva-Maria Grischke, Christian Schem, Michael P. Lux, Mustafa Deryal, Oliver Hoffmann, Bernhard Heinrich, Georg Kunz, Kristina Lübbe, Petra Krabisch, Arndt Hartmann, Philip Raeth, Sabine Kasimir-Bauer, Hans-Christian Kolberg
Journal: Clinical Cancer Research
Clin Cancer Res (2025) 31 (12_Supplement): P2-11-17.
https://doi.org/10.1158/1557-3265.SABCS24-P2-11-17
Published: 13 June 2025
View article titled, Abstract P2-11-17: Atezolizumab in combination w/ polychemotherapy w/ or without a pretherapeutic immune therapy window in patients w/ early triple negative breast cancer (eTNBC) & low tumor burden – prospective data from the randomized neoadjuvant neoMono trial
Journal Articles

Impact of RNA Signatures on pCR and Survival after 12-Week Neoadjuvant Pertuzumab plus Trastuzumab with or without Paclitaxel in the WSG-ADAPT HER2+/HR− Trial

Open Access
Monika Graeser, Oleg Gluz, Claudia Biehl, Daniel Ulbrich-Gebauer, Matthias Christgen, Jenci Palatty, Sherko Kuemmel, Eva-Maria Grischke, Doris Augustin, Michael Braun, Jochem Potenberg, Rachel Wuerstlein, Katja Krauss, Claudia Schumacher, Helmut Forstbauer, Toralf Reimer, Andrea Stefek, Hans Holger Fischer, Enrico Pelz, Christine zu Eulenburg, Ronald Kates, Hua Ni, Cornelia Kolberg-Liedtke, Friedrich Feuerhake, Hans Heinrich Kreipe, Ulrike Nitz, Nadia Harbeck
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (4): 805–814.
https://doi.org/10.1158/1078-0432.CCR-22-1587
Published: 16 February 2023
View article titled, Impact of RNA Signatures on pCR and Survival after 12-Week Neoadjuvant Pertuzumab plus Trastuzumab with or without Paclitaxel in the WSG-ADAPT HER2+/HR− Trial
Open the PDF for Impact of RNA Signatures on pCR and Survival after 12-Week Neoadjuvant Pertuzumab plus Trastuzumab with or without Paclitaxel in the WSG-ADAPT HER2+/HR− Trial in another window
Includes: Supplementary data
Journal Articles

De-escalated Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer (TNBC): Impact of Molecular Markers and Final Survival Analysis of the WSG-ADAPT-TN Trial

Available to Purchase
Oleg Gluz, Ulrike Nitz, Cornelia Kolberg-Liedtke, Aleix Prat, Matthias Christgen, Sherko Kuemmel, Mohammad Parsa Mohammadian, Daniel Gebauer, Ronald Kates, Laia Paré, Eva-Maria Grischke, Helmut Forstbauer, Michael Braun, Mathias Warm, John Hackmann, Christoph Uleer, Bahriye Aktas, Claudia Schumacher, Rachel Wuerstlein, Monika Graeser, Enrico Pelz, Katarzyna Jóźwiak, Christine zu Eulenburg, Hans Heinrich Kreipe, Nadia Harbeck, on behalf of the ADAPT TN investigators
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (22): 4995–5003.
https://doi.org/10.1158/1078-0432.CCR-22-0482
Published: 14 November 2022
View article titled, De-escalated Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer (TNBC): Impact of Molecular Markers and Final Survival Analysis of the WSG-ADAPT-TN Trial
Open the PDF for De-escalated Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer (TNBC): Impact of Molecular Markers and Final Survival Analysis of the WSG-ADAPT-TN Trial in another window
Includes: Supplementary data